NO822102L - Fremgangsmaate for fremstilling av farmasoeytisk aktive 2-aryl-3,4-diaza-bicykloalkenon-derivater - Google Patents
Fremgangsmaate for fremstilling av farmasoeytisk aktive 2-aryl-3,4-diaza-bicykloalkenon-derivaterInfo
- Publication number
- NO822102L NO822102L NO822102A NO822102A NO822102L NO 822102 L NO822102 L NO 822102L NO 822102 A NO822102 A NO 822102A NO 822102 A NO822102 A NO 822102A NO 822102 L NO822102 L NO 822102L
- Authority
- NO
- Norway
- Prior art keywords
- diaza
- bicyclo
- tetrahydroquinolin
- methyl
- azepin
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title claims description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 8
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 239000001257 hydrogen Substances 0.000 claims abstract description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- -1 cycloalkane carboxylic acid Chemical class 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000000463 material Substances 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 230000009424 thromboembolic effect Effects 0.000 abstract description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 9
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 8
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- HRVRAYIYXRVAPR-UHFFFAOYSA-N 1,3,4,5-tetrahydro-1-benzazepin-2-one Chemical group N1C(=O)CCCC2=CC=CC=C21 HRVRAYIYXRVAPR-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 1
- JECPTYOLILQNAT-UHFFFAOYSA-N 3-(4-propoxyphenyl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound C1=CC(OCCC)=CC=C1C1=NNC(=O)CC1 JECPTYOLILQNAT-UHFFFAOYSA-N 0.000 description 1
- KSGYMLDMYPAMFV-UHFFFAOYSA-N 3-phenyl-4,5-dihydro-1h-pyridazin-6-one Chemical class N1C(=O)CCC(C=2C=CC=CC=2)=N1 KSGYMLDMYPAMFV-UHFFFAOYSA-N 0.000 description 1
- NMSRALOLNIBERV-UHFFFAOYSA-N 4,5,6,6a-tetrahydro-3ah-cyclopenta[c]furan-1,3-dione Chemical compound C1CCC2C(=O)OC(=O)C21 NMSRALOLNIBERV-UHFFFAOYSA-N 0.000 description 1
- WXQSPVFHVLTAFJ-UHFFFAOYSA-N 5-(6-oxo-4,5-dihydro-1h-pyridazin-3-yl)-1,3-dihydroindol-2-one Chemical class C=1C=C2NC(=O)CC2=CC=1C1=NNC(=O)CC1 WXQSPVFHVLTAFJ-UHFFFAOYSA-N 0.000 description 1
- SLHSCTCINOLPIL-UHFFFAOYSA-N 6-(4-methyl-6-oxo-4,5-dihydro-1h-pyridazin-3-yl)-3,4-dihydro-1h-quinolin-2-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(NC(=O)CC2)C2=C1 SLHSCTCINOLPIL-UHFFFAOYSA-N 0.000 description 1
- XQFYVUUOCXEQCP-UHFFFAOYSA-N 6-(6-oxo-4,5-dihydro-1h-pyridazin-3-yl)-3,4-dihydro-1h-quinolin-2-one Chemical class N1C(=O)CCC(C=2C=C3CCC(=O)NC3=CC=2)=N1 XQFYVUUOCXEQCP-UHFFFAOYSA-N 0.000 description 1
- 238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- DLDCKPBXRSRJPV-UHFFFAOYSA-N cyclobutanecarbonyl cyclobutanecarboxylate Chemical compound C1CCC1C(=O)OC(=O)C1CCC1 DLDCKPBXRSRJPV-UHFFFAOYSA-N 0.000 description 1
- YZFOGXKZTWZVFN-UHFFFAOYSA-N cyclopentane-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CCCC1 YZFOGXKZTWZVFN-UHFFFAOYSA-N 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000000936 membranestabilizing effect Effects 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19813124699 DE3124699A1 (de) | 1981-06-24 | 1981-06-24 | Neue 2-aryl-3,4-diaza-bicyclo(4.n.0.)alken-(2)-one-(5),verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO822102L true NO822102L (no) | 1982-12-27 |
Family
ID=6135223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO822102A NO822102L (no) | 1981-06-24 | 1982-06-23 | Fremgangsmaate for fremstilling av farmasoeytisk aktive 2-aryl-3,4-diaza-bicykloalkenon-derivater |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US4474785A (hu) |
| EP (1) | EP0068310B1 (hu) |
| JP (1) | JPS58975A (hu) |
| AT (1) | ATE8891T1 (hu) |
| AU (1) | AU548396B2 (hu) |
| CA (1) | CA1171412A (hu) |
| CS (1) | CS227692B2 (hu) |
| DE (2) | DE3124699A1 (hu) |
| DK (1) | DK281482A (hu) |
| ES (1) | ES513391A0 (hu) |
| FI (1) | FI73425C (hu) |
| GR (1) | GR76010B (hu) |
| HU (1) | HU188179B (hu) |
| IL (1) | IL66009A (hu) |
| NO (1) | NO822102L (hu) |
| ZA (1) | ZA824438B (hu) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4591591A (en) * | 1984-03-08 | 1986-05-27 | Eli Lilly And Company | Pyridazinone derivatives as inotropic agents |
| US4647564A (en) * | 1984-05-14 | 1987-03-03 | Eli Lilly And Company | Inotropic agents |
| IL75122A (en) * | 1984-05-14 | 1989-02-28 | Lilly Co Eli | 3-methyl-5-(tetrahydro-6-oxopyridazin-3-yl)indoline derivatives,their preparation and use |
| JPS6135240A (ja) * | 1984-07-27 | 1986-02-19 | 新東工業株式会社 | フルモ−ルド用発泡成形体 |
| US4617302A (en) * | 1984-10-15 | 1986-10-14 | Eli Lilly And Company | Inotropic agents |
| JPH0662608B2 (ja) * | 1985-08-26 | 1994-08-17 | 大塚製薬株式会社 | カルボスチリル誘導体 |
| DE3535170A1 (de) * | 1985-10-02 | 1987-04-16 | Basf Ag | Verwendung von 2-aryl-3,4-diaza-bicyclo(4.n.0)alken-(2)-onen-(5) zur behandlung der herzinsuffizienz |
| DE3535949A1 (de) * | 1985-10-09 | 1987-04-09 | Basf Ag | Kombinationspraeparat |
| DE3535947A1 (de) * | 1985-10-09 | 1987-04-09 | Basf Ag | Kombinationspraeparat |
| DE3631085A1 (de) * | 1986-09-12 | 1988-03-24 | Boehringer Mannheim Gmbh | Heterocyclisch substituierte indolinone, verfahren zu ihrer herstellung, arzneimittel sowie zwischenprodukte |
| JPH02153730A (ja) * | 1988-10-24 | 1990-06-13 | Kanayama Kasei Kk | 断熱を要する機器の表面材 |
| US6168956B1 (en) | 1991-05-29 | 2001-01-02 | Beckman Coulter, Inc. | Multiple component chromatographic assay device |
| US5869345A (en) | 1991-05-29 | 1999-02-09 | Smithkline Diagnostics, Inc. | Opposable-element assay device employing conductive barrier |
| US5607863A (en) | 1991-05-29 | 1997-03-04 | Smithkline Diagnostics, Inc. | Barrier-controlled assay device |
| JP3442815B2 (ja) * | 1992-05-13 | 2003-09-02 | 第一製薬株式会社 | ジアザビシクロアルケン誘導体 |
| SE9901825D0 (sv) | 1999-05-20 | 1999-05-20 | Amersham Pharm Biotech Ab | Foamed material filled with inner material |
| EP3130583B1 (en) * | 2012-04-05 | 2024-01-03 | CHDI Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| US9884853B2 (en) | 2013-09-26 | 2018-02-06 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| ES2754473T3 (es) * | 2013-09-26 | 2020-04-17 | Chdi Foundation Inc | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas, y método de uso de los mismos |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH557820A (de) * | 1970-11-12 | 1975-01-15 | Sandoz Ag | Verfahren zur herstellung von neuen 2-(2-hydroxyalkyl)4,5-dihydro-pyridazin (2h)-3-onen. |
| US3746712A (en) * | 1971-06-08 | 1973-07-17 | A Ross | 6-(substituted-phenyl)-5-methyl-4,5-dihydro-3(2h)-pyridazinones |
| US3812256A (en) * | 1971-06-08 | 1974-05-21 | American Cyanamid Co | Novel method for lowering blood pressure in mammals |
| US3824271A (en) * | 1972-07-20 | 1974-07-16 | American Cyanamid Co | 3-alkyl-3-(benzoyl)propionitriles |
| US3888901A (en) * | 1972-07-20 | 1975-06-10 | American Cyanamid Co | Process of preparing 3-alkyl-3-(benzoyl)propionitriles |
| DE2304977A1 (de) * | 1973-02-01 | 1974-08-08 | Basf Ag | Neue dihydropyridazinone |
| US4070470A (en) * | 1974-06-24 | 1978-01-24 | Otsuka Pharmaceutical Co., Ltd. | Platelet aggregation inhibiting carbostyrils, their compositions and method of use |
| DE2727481A1 (de) * | 1977-06-18 | 1979-01-11 | Basf Ag | Dihydropyridazone und dihydropyridazone enthaltende therapeutische mittel |
| JPS54135785A (en) * | 1978-04-12 | 1979-10-22 | Yoshitomi Pharmaceut Ind Ltd | Pyridazinone derivative and its preparation |
| DE2845220A1 (de) * | 1978-10-17 | 1980-04-30 | Yoshitomi Pharmaceutical | Pyridazinon-derivate, ihre salze mit saeuren, verfahren zu ihrer herstellung und ihre verwendung bei der behandlung von thrombosen und hypertonie |
| US4258185A (en) * | 1978-10-17 | 1981-03-24 | Yoshitomi Pharmaceutical Industries, Ltd. | Pyridazinone compounds |
| DE2845456A1 (de) * | 1978-10-19 | 1980-08-14 | Merck Patent Gmbh | 6-arylpyridazin-3-one und verfahren zu ihrer herstellung |
| DE2854191A1 (de) * | 1978-12-15 | 1980-07-03 | Basf Ag | Dihydropyridazinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende therapeutische mittel |
| DE2854475A1 (de) * | 1978-12-16 | 1980-07-03 | Basf Ag | Neue 3,4-diaza-bicyclo eckige klammer auf 4.1.0 eckige klammer zu hepten-(2)- one-(5), verfahren zu ihrer herstellung und diese verbindungen enthaltende therapeutische mittel |
-
1981
- 1981-06-24 DE DE19813124699 patent/DE3124699A1/de not_active Withdrawn
-
1982
- 1982-05-13 GR GR68151A patent/GR76010B/el unknown
- 1982-06-04 US US06/385,272 patent/US4474785A/en not_active Expired - Fee Related
- 1982-06-07 CA CA000404625A patent/CA1171412A/en not_active Expired
- 1982-06-08 IL IL66009A patent/IL66009A/xx unknown
- 1982-06-16 EP EP82105281A patent/EP0068310B1/de not_active Expired
- 1982-06-16 DE DE8282105281T patent/DE3260540D1/de not_active Expired
- 1982-06-16 AT AT82105281T patent/ATE8891T1/de active
- 1982-06-18 FI FI822203A patent/FI73425C/fi not_active IP Right Cessation
- 1982-06-23 NO NO822102A patent/NO822102L/no unknown
- 1982-06-23 HU HU822034A patent/HU188179B/hu not_active IP Right Cessation
- 1982-06-23 ES ES513391A patent/ES513391A0/es active Granted
- 1982-06-23 JP JP57106986A patent/JPS58975A/ja active Pending
- 1982-06-23 ZA ZA824438A patent/ZA824438B/xx unknown
- 1982-06-23 DK DK281482A patent/DK281482A/da not_active Application Discontinuation
- 1982-06-23 AU AU85153/82A patent/AU548396B2/en not_active Ceased
- 1982-06-24 CS CS824710A patent/CS227692B2/cs unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0068310B1 (de) | 1984-08-08 |
| FI73425C (fi) | 1987-10-09 |
| DE3124699A1 (de) | 1983-01-13 |
| JPS58975A (ja) | 1983-01-06 |
| GR76010B (hu) | 1984-08-03 |
| EP0068310A1 (de) | 1983-01-05 |
| ATE8891T1 (de) | 1984-08-15 |
| ES8304969A1 (es) | 1983-03-16 |
| IL66009A0 (en) | 1982-09-30 |
| ES513391A0 (es) | 1983-03-16 |
| FI73425B (fi) | 1987-06-30 |
| CA1171412A (en) | 1984-07-24 |
| US4474785A (en) | 1984-10-02 |
| DE3260540D1 (en) | 1984-09-13 |
| FI822203A0 (fi) | 1982-06-18 |
| ZA824438B (en) | 1983-05-25 |
| CS227692B2 (en) | 1984-05-14 |
| AU8515382A (en) | 1983-01-13 |
| IL66009A (en) | 1986-02-28 |
| DK281482A (da) | 1982-12-25 |
| AU548396B2 (en) | 1985-12-12 |
| FI822203L (fi) | 1982-12-25 |
| HU188179B (en) | 1986-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO822102L (no) | Fremgangsmaate for fremstilling av farmasoeytisk aktive 2-aryl-3,4-diaza-bicykloalkenon-derivater | |
| US4851406A (en) | Heterocyclic-substituted indoles and pharmaceutical compositions containing them | |
| US4795749A (en) | Imidazopyrroloquinoxaline compounds | |
| DE69212346T2 (de) | Diazotierte heterocyclische Derivate aus Stickstoff, substituiert durch eine Biphenylgruppe, ihre Herstellung, und diese enthaltende pharmazeutische Zubereitungen | |
| JPH02288868A (ja) | 複素環式化合物およびその製造法 | |
| DE3935514A1 (de) | Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
| MXPA04008680A (es) | Derivados de pirazol triciclicos, procedimientos para su preparacion y su uso como agentes anti-tumorales. | |
| HU196788B (en) | Process for producing substituted dihydro-pyridine derivatives and pharmaceutical compositions containing them | |
| JP2010013475A (ja) | 新規な置換ピラゾール誘導体 | |
| JP2001506280A (ja) | ２−置換４，５−ジアリールイミダゾール | |
| SK284295B6 (sk) | Derivát 4-(arylaminometylén)-2,4-dihydropyrazol-3-ónu, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje | |
| JPH0657710B2 (ja) | イミダゾジアゼピン誘導体 | |
| JP2010513386A (ja) | キナーゼ阻害剤としてのインドリルマレイミド誘導体 | |
| AU728360B2 (en) | Thienylcyclohexanone derivatives as ligands of the gabaa alpha5 receptor subtype | |
| NO840213L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive 6-(acylaminoaryl)-3(2h)-pyridazinon-derivater | |
| JPH039114B2 (hu) | ||
| US4874756A (en) | Benzodipyrroles, processes for the preparation thereof and pharmaceutical compositions containing them | |
| DK159969B (da) | Pyridazinderivater, der har psykotropisk virkning, og laegemidler indeholdende dem | |
| US3586681A (en) | 1,4,5,6-tetrahydropyridazines | |
| EP0280224B1 (de) | Substituierte 3H-Indole, Verfahren zu ihrer Herstellung sowie Arzneimittel | |
| JPS6159626B2 (hu) | ||
| US4053600A (en) | Tricyclic 1,2,4-triazolo-quinazolines | |
| US4544562A (en) | 6-Aryl-4,5-dihydro-3(2H)-pyridazinones, and their use as anti-hypertensive and anti-thrombocyte agents | |
| US4772598A (en) | 2-aryl-3,4-diazabicyclo(4.n.O)alk-2-en-5-ones for the preparation of an agent for treating cardiac insufficiency | |
| US5053508A (en) | Fused heterotricyclic imides with psychotropic activity and intermedrates thereof |